GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zogenix Inc (NAS:ZGNX) » Definitions » Shiller PE Ratio

Zogenix (Zogenix) Shiller PE Ratio : (As of May. 06, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Zogenix Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zogenix Shiller PE Ratio Historical Data

The historical data trend for Zogenix's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zogenix Shiller PE Ratio Chart

Zogenix Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zogenix Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zogenix's Shiller PE Ratio

For the Biotechnology subindustry, Zogenix's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zogenix's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zogenix's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Zogenix's Shiller PE Ratio falls into.



Zogenix Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Zogenix's E10 for the quarter that ended in Dec. 2021 is calculated as:

For example, Zogenix's adjusted earnings per share data for the three months ended in Dec. 2021 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2021 (Change)*Current CPI (Dec. 2021)
=-0.98/117.6295*117.6295
=-0.980

Current CPI (Dec. 2021) = 117.6295.

Zogenix Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201203 -1.280 96.783 -1.556
201206 -2.080 96.819 -2.527
201209 -1.680 97.633 -2.024
201212 -0.080 96.871 -0.097
201303 -1.680 98.209 -2.012
201306 -1.040 98.518 -1.242
201309 -0.800 98.790 -0.953
201312 -2.240 98.326 -2.680
201403 -1.600 99.695 -1.888
201406 3.590 100.560 4.199
201409 -0.730 100.428 -0.855
201412 -1.120 99.070 -1.330
201503 -1.190 99.621 -1.405
201506 3.780 100.684 4.416
201509 -0.650 100.392 -0.762
201512 -0.360 99.792 -0.424
201603 -0.420 100.470 -0.492
201606 -0.760 101.688 -0.879
201609 -0.690 101.861 -0.797
201612 -0.950 101.863 -1.097
201703 -0.860 102.862 -0.983
201706 -0.930 103.349 -1.059
201709 -1.680 104.136 -1.898
201712 -1.170 104.011 -1.323
201803 -0.870 105.290 -0.972
201806 -0.830 106.317 -0.918
201809 -1.080 106.507 -1.193
201812 -0.530 105.998 -0.588
201903 -0.830 107.251 -0.910
201906 -0.890 108.070 -0.969
201909 -6.750 108.329 -7.329
201912 -1.260 108.420 -1.367
202003 -0.540 108.902 -0.583
202006 -0.960 108.767 -1.038
202009 -1.080 109.815 -1.157
202012 -1.260 109.897 -1.349
202103 -1.000 111.754 -1.053
202106 -1.050 114.631 -1.077
202109 -1.040 115.734 -1.057
202112 -0.980 117.630 -0.980

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zogenix  (NAS:ZGNX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Zogenix Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Zogenix's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zogenix (Zogenix) Business Description

Traded in Other Exchanges
N/A
Address
5959 Horton Street, Suite 500, Emeryville, CA, USA, 94608
Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.
Executives
Erle T Mast director C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Cam L Garner director PO BOX 675866, RANCHO SANTE FE CA 92067
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Denelle J Waynick director C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary E. Stutts director C/O ZOGENIX, INC. 5959 HORTON STREET EMERYVILLE CA 94608
Ashish M Sagrolikar officer: EVP & CHIEF COMMERCIAL OFFICER C/O ZOGENIX, INC. 5858 HORTON STREET, #455 EMERYVILLE CA 94608
Gail M Farfel officer: EVP/Chief Development Officer 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Bradley S. Galer officer: EVP/Chief Medical Officer C/O ZOGENIX, INC. 12400 HIGH BLUFF DR., SUITE 650 SAN DIEGO CA 92130
Stephen J Farr director, officer: President and CEO [email protected] EMERYVILLE CA 94608
Mark C Wiggins director 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Louis C Bock director C/O BANKAMERICA VENTURES, 950 TOWER LANE STE 700, FOSTER CITY CA 94404
James B Breitmeyer director
Shawnte Mitchell officer: EVP, GC and Secretary 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael P Smith officer: EVP, CFO, Treasurer & Sec. 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5